258 related articles for article (PubMed ID: 34841220)
1. Targeted Imaging of CD206 Expressing Tumor-Associated M2-like Macrophages Using Mannose-Conjugated Antibiofouling Magnetic Iron Oxide Nanoparticles.
Li Y; Wu H; Ji B; Qian W; Xia S; Wang L; Xu Y; Chen J; Yang L; Mao H
ACS Appl Bio Mater; 2020 Jul; 3(7):4335-4347. PubMed ID: 34841220
[TBL] [Abstract][Full Text] [Related]
2. Probing and Enhancing Ligand-Mediated Active Targeting of Tumors Using Sub-5 nm Ultrafine Iron Oxide Nanoparticles.
Xu Y; Wu H; Huang J; Qian W; Martinson DE; Ji B; Li Y; Wang YA; Yang L; Mao H
Theranostics; 2020; 10(6):2479-2494. PubMed ID: 32194814
[No Abstract] [Full Text] [Related]
3. Anti-HER2 antibody and ScFvEGFR-conjugated antifouling magnetic iron oxide nanoparticles for targeting and magnetic resonance imaging of breast cancer.
Chen H; Wang L; Yu Q; Qian W; Tiwari D; Yi H; Wang AY; Huang J; Yang L; Mao H
Int J Nanomedicine; 2013; 8():3781-94. PubMed ID: 24124366
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD206 antibody-conjugated Fe
Zhou Y; Que KT; Tang HM; Zhang P; Fu QM; Liu ZJ
Oncol Lett; 2020 Dec; 20(6):298. PubMed ID: 33101492
[TBL] [Abstract][Full Text] [Related]
5. [Anti-CD206 antibody-conjugated Fe
Fu Q; Tang H; Zhang P; Que K; Liu Z; Zhou Y
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Feb; 40(2):246-254. PubMed ID: 32376536
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab and near infrared probe conjugated iron oxide nanoparticles for vascular endothelial growth factor targeted MR and optical imaging.
Lin R; Huang J; Wang L; Li Y; Lipowska M; Wu H; Yang J; Mao H
Biomater Sci; 2018 May; 6(6):1517-1525. PubMed ID: 29652061
[TBL] [Abstract][Full Text] [Related]
7. Fluorinated PLGA-PEG-Mannose Nanoparticles for Tumor-Associated Macrophage Detection by Optical Imaging and MRI.
Zambito G; Deng S; Haeck J; Gaspar N; Himmelreich U; Censi R; Löwik C; Di Martino P; Mezzanotte L
Front Med (Lausanne); 2021; 8():712367. PubMed ID: 34513879
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive Imaging of CD206-Positive M2 Macrophages as an Early Biomarker for Post-Chemotherapy Tumor Relapse and Lymph Node Metastasis.
Zhang C; Yu X; Gao L; Zhao Y; Lai J; Lu D; Bao R; Jia B; Zhong L; Wang F; Liu Z
Theranostics; 2017; 7(17):4276-4288. PubMed ID: 29158825
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy using microwave ablation and d-mannose-chelated iron oxide nanoparticles inhibits hepatocellular carcinoma progression.
Cui R; Wang L; Zhang D; Zhang K; Dou J; Dong L; Zhang Y; Wu J; Tan L; Yu J; Liang P
Acta Pharm Sin B; 2022 Sep; 12(9):3475-3485. PubMed ID: 36176908
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a CD206-Targeted Peptide for PET Imaging of Macrophages in Syngeneic Mouse Models of Cancer.
Parker CC; Bin Salam A; Song PN; Gallegos C; Hunt A; Yates C; Jaynes J; Lopez H; Massicano AVF; Sorace AG; Fernandez S; Houson HA; Lapi SE
Mol Pharm; 2023 May; 20(5):2415-2425. PubMed ID: 37014648
[TBL] [Abstract][Full Text] [Related]
11. Targeting Pro-Tumoral Macrophages in Early Primary and Metastatic Breast Tumors with the CD206-Binding mUNO Peptide.
Lepland A; Asciutto EK; Malfanti A; Simón-Gracia L; Sidorenko V; Vicent MJ; Teesalu T; Scodeller P
Mol Pharm; 2020 Jul; 17(7):2518-2531. PubMed ID: 32421341
[TBL] [Abstract][Full Text] [Related]
12. DOT corrected fluorescence molecular tomography using targeted contrast agents for small animal tumor imaging.
Tan Y; Cao Z; Sajja HK; Lipowska M; Wang YA; Yang L; Jiang H
J Xray Sci Technol; 2013; 21(1):43-52. PubMed ID: 23507851
[TBL] [Abstract][Full Text] [Related]
13. PEG-
Li Y; Lin R; Wang L; Huang J; Wu H; Cheng G; Zhou Z; MacDonald T; Yang L; Mao H
J Mater Chem B; 2015 May; 3(17):3591-3603. PubMed ID: 26594360
[TBL] [Abstract][Full Text] [Related]
14. Targeting and repolarizing M2-like tumor-associated macrophage-mediated MR imaging and tumor immunotherapy by biomimetic nanoparticles.
Chong L; Jiang YW; Wang D; Chang P; Xu K; Li J
J Nanobiotechnology; 2023 Oct; 21(1):401. PubMed ID: 37907987
[TBL] [Abstract][Full Text] [Related]
15. Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy.
Figueiredo P; Lepland A; Scodeller P; Fontana F; Torrieri G; Tiboni M; Shahbazi MA; Casettari L; Kostiainen MA; Hirvonen J; Teesalu T; Santos HA
Acta Biomater; 2021 Oct; 133():231-243. PubMed ID: 33011297
[TBL] [Abstract][Full Text] [Related]
16. The GRP94 Inhibitor PU-WS13 Decreases M2-like Macrophages in Murine TNBC Tumors: A Pharmaco-Imaging Study with
Bouchard A; Sikner H; Baverel V; Garnier AR; Monterrat M; Moreau M; Limagne E; Garrido C; Kohli E; Collin B; Bellaye PS
Cells; 2021 Dec; 10(12):. PubMed ID: 34943901
[TBL] [Abstract][Full Text] [Related]
17. Interaction of Iron Oxide Nanoparticles with Macrophages Is Influenced Distinctly by "Self" and "Non-Self" Biological Identities.
Portilla Y; Mulens-Arias V; Daviu N; Paradela A; Pérez-Yagüe S; Barber DF
ACS Appl Mater Interfaces; 2023 Aug; 15(30):35906-35926. PubMed ID: 37478159
[TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapeutic effect of carboxymethylated β-d-glucan coupled with iron oxide nanoparticles via reprogramming tumor-associated macrophages.
Su Y; Yang F; Wang M; Cheung PCK
Int J Biol Macromol; 2023 Feb; 228():692-705. PubMed ID: 36566807
[TBL] [Abstract][Full Text] [Related]
19. Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast Cancer.
Esser AK; Ross MH; Fontana F; Su X; Gabay A; Fox GC; Xu Y; Xiang J; Schmieder AH; Yang X; Cui G; Scott M; Achilefu S; Chauhan J; Fletcher S; Lanza GM; Weilbaecher KN
Theranostics; 2020; 10(17):7510-7526. PubMed ID: 32685002
[TBL] [Abstract][Full Text] [Related]
20. Tumor Penetrating Theranostic Nanoparticles for Enhancement of Targeted and Image-guided Drug Delivery into Peritoneal Tumors following Intraperitoneal Delivery.
Gao N; Bozeman EN; Qian W; Wang L; Chen H; Lipowska M; Staley CA; Wang YA; Mao H; Yang L
Theranostics; 2017; 7(6):1689-1704. PubMed ID: 28529645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
